Xcout Intel
Artios competitors & alternatives
The 12 closest competitors and alternatives to Artios among biotechnology companies — ranked by similarity to what Artios actually does, not by market-cap band.
Subscribe to see Artios’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Artios
Artios Pharma is an independent biotechnology company headquartered at the Babraham Research Campus in Cambridge, United Kingdom, focused on discovering novel cancer therapies through DNA damage response mechanisms.
Artios at a glance
Artios is a biotechnology company headquartered in United Kingdom. It has raised at least $231.5M across the 3 funding rounds on record. Its most recent funding round, Series D, raised $115M in November 2025. Xcout tracks 12 named people at Artios, including Michael T. Andriole (President, Chief Executive Officer, and Director).
Artios leadership
- Michael T. AndriolePresident, Chief Executive Officer, and Director
- Christine SilversteinChief Financial Officer
- Graeme SmithChief Scientific Officer
- Ian SmithChief Medical Officer
- Jeremy B. FitchChief Business Officer
- Roy WareChief Manufacturing and Technology Officer
6 more named people on record for Artios, with roles, board committees and tenure — see the full roster →
Artios funding rounds
At least $231.5M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series D | $115M | — | |
| Series B | $84M | 4 named | |
| Series A | $32.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Artios competitors
Ranked by semantic similarity — how close each company is to Artios by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Apollo Therapeutics is a biopharmaceutical company with headquarters located in Cambridge, United Kingdom, alongside offices in Boston, Massachusetts. The company advances breakthrough science to build a portfolio of innovative therapeutics.
Similar biotechnology company
Mission Therapeutics is a drug discovery and development company recognized as a global leader in targeting deubiquitylating enzymes. Founded in 2011, the firm is based at the Babraham Research Campus in Cambridge, United Kingdom.
Similar biotechnology company
PhoreMost Ltd is a Cambridge, United Kingdom-based biotechnology and drug discovery company dedicated to turning scientific breakthroughs into life-changing cancer therapies.
Biotech
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Biotech
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Similar biotechnology company
Cyteir Therapeutics, Inc. was a biotechnology company focused on developing novel cancer therapeutics leveraging synthetic lethality and DNA damage repair. Founded in 2012, the company was formerly publicly traded on Nasdaq before officially ceasing operations in 2024.
Biotech
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Similar biotechnology company
Cumulus Oncology operates Europe's first oncology biotech creation engine, identifying promising therapeutic assets and spinning out specialized companies. Headquartered in Edinburgh, Scotland, the company secured £9m in seed financing to accelerate its oncology drug development model. It employs a lean team dedicated to oncology asset creation.
Similar biotechnology company
Pathios Therapeutics Limited is a biotech company established in 2017 and registered in England and Wales, focusing on the discovery and development of first-in-class therapies.
Similar biotechnology company
Curis, Inc. is a biotechnology company headquartered in Lexington, Massachusetts. The company is engaged in the research and development of drug candidates for the treatment of human cancers.
Biotech
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Biotech
Rakovina Therapeutics, Inc. focuses on the development of new cancer treatments based on novel DNA-damage response technologies. It engages in developing precision medicines that selectively target and kill cancer cells using science to discover and advance innovative cancer treatments with the potential to improve patient outcomes across multiple tumor types. The company was founded on May 6, 2019 and is headquartered in Vancouver, Canada.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Artios and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Artiosand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →